Publications by authors named "H Barnacle"
Article Synopsis
- A population pharmacokinetic analysis was performed on samples from a trial assessing the effectiveness of a combined inhaler treatment for Chronic Obstructive Pulmonary Disease (COPD) patients.
- The study compared once-daily triple therapy (fluticasone furoate-umeclidinium-vilanterol) to twice-daily dual therapy (budesonide/formoterol) over 24 weeks, involving 74 patients who provided samples.
- Results from Monte Carlo simulations showed that drug concentrations of the three components in the combination therapy were similar to those observed when the drugs were administered individually or in dual combinations.
FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care Med
August 2017
Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid (ICS)/long-acting β-agonist (LABA) therapy in patients with chronic obstructive pulmonary disease (COPD) are limited.
Objectives: We compared the effects of once-daily triple therapy on lung function and health-related quality of life with twice-daily ICS/LABA therapy in patients with COPD.
Methods: The FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) trial was a randomized, double-blind, double-dummy study comparing 24 weeks of once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 μg/62.